U.S. PRP And Stem Cell Alopecia Treatment Market Size to Hit Around USD 630.84 Mn by 2034

The U.S. PRP and stem cell alopecia treatment market size was exhibited at USD 255.25 million in 2024 and is projected to hit around USD 630.84 million by 2034, growing at a CAGR of 9.47% during the forecast period 2025 to 2034.

?????????????? ?????? ???????? ???????????? ????????????: https://www.novaoneadvisor.com/report/sample/9007

U.S. PRP And Stem Cell Alopecia Treatment Market Key Takeaways:

• The platelet rich plasma therapy led the market and accounted for the largest revenue share of 73.49% in 2024.
• Stem cell therapy is expected to grow significantly at a CAGR of 12.47% over the forecast period.
• Androgenic alopecia dominated the market and accounted for the largest revenue share of 71.51% in 2024
• Dermatology clinics dominated the market and accounted for the largest revenue share of 70.0% in 2024
• Hospitals are expected to grow at the fastest CAGR over the forecast period.

This growth is attributed to the increasing number of people suffering from alopecia and rising awareness of novel treatment procedures. PRP and stem cell treatments are preferred over conventional drugs, such as corticosteroids, due to their efficiency, faster hair regrowth, and ease of administration. In addition, the growing preference for minimally invasive procedures over surgeries contributes to market expansion. Furthermore, most alopecia treatments are performed by dermatologists in private clinics, further boosting the market's growth in the U.S.

Alopecia, characterized by localized hair loss, occurs when the immune system attacks hair follicles. This condition can lead to noticeable patches as hair falls out. Treatments such as stem cell therapy and platelet-rich plasma (PRP) are gaining traction as regenerative medicine options. These minimally invasive therapies stimulate and strengthen hair regrowth rather than surgically removing damaged tissue. The increasing preference for such non-invasive procedures over traditional surgeries is expected to significantly enhance the U.S. market for PRP and stem cell alopecia treatments.

Patients and dermatologists increasingly favor these advanced therapies over conventional medications such as corticosteroids due to their effectiveness and quicker results in promoting hair regrowth. Furthermore, the ease of administering these treatments contributes to their growing popularity. As awareness of alopecia rises and more patients seek effective solutions, the demand for PRP and stem cell therapies is anticipated to grow.

Furthermore, the increasing prevalence of alopecia and advancements in treatment technologies provide a tremendous growth opportunity for the market. The proliferation of specialized dermatology clinics offering tailored therapies at lower costs than hospitals is also a significant growth factor. Moreover, ongoing research into these treatments' efficacy and potential applications may drive market interest. With a favorable regulatory environment and a shift towards patient-centered care, the PRP and stem cell alopecia treatment market is poised for substantial growth in the coming years.

U.S. PRP And Stem Cell Alopecia Treatment Market By Treatment Insights

The platelet rich plasma therapy led the market and accounted for the largest revenue share of 73.49% in 2024 attributed to the growing acceptance of regenerative medicine practices among healthcare professionals and patients, highlighting PRP's potential for enhancing healing procedures in various medical fields, including orthopedics and dermatology. In addition, the autologous nature of PRP derived from the patient's blood eliminates risks of disease transmission and allergic reactions, making it a safer option. Furthermore, ongoing research reveals its effectiveness in treating conditions such as alopecia, which further fuels interest and investment in this therapy.

U.S. PRP And Stem Cell Alopecia Treatment Market By Indication Insights

Androgenic alopecia dominated the market and accounted for the largest revenue share of 71.51% in 2024 attributed to its high prevalence, affecting approximately 50 million men and 30 million women. As the population ages, particularly baby boomers and Gen X, the demand for effective treatments increases. In addition, advances in understanding the genetic and hormonal factors contributing to this condition have led to innovative therapies, including PRP and stem cell treatments, which offer promising results in hair restoration.

U.S. PRP And Stem Cell Alopecia Treatment Market By End-use Insights

Dermatology clinics dominated the market and accounted for the largest revenue share of 70.0% in 2024 driven by the rising prevalence of skin conditions and hair loss disorders, such as androgenic alopecia. As awareness of advanced treatment options increases, patients seek specialized care in dermatology clinics equipped with the latest technologies for effective treatments. In addition, the aging population, which is more susceptible to skin issues, drives demand for dermatological services, contributing to expanding clinics nationwide.

Hospitals are expected to grow at the fastest CAGR over the forecast period, owing to the increasing incidence of skin diseases and conditions requiring specialized treatment, leading hospitals to expand their dermatology departments. In addition, hospitals are often equipped with cutting-edge facilities for conducting clinical trials and research on innovative therapies such as PRP and stem cell treatments. Furthermore, integrating advanced treatments within hospital settings enhances patient trust and drives growth in this market segment.

Some of the prominent players in the U.S. PRP and stem cell alopecia treatment market include:

• Bauman Medical Group, P.A.
• Virginia Surgical Center
• Nova Medical Hair Transplant
• Chicago Hair Transplant Clinic
• Dr. V Medical Aesthetics
• City Facial Plastics
• Orange County Hair Restoration
• MAXIM Hair Restoration
• New Jersey Hair Restoration Center
• Hair Restoration Institute of Minnesota
• Morgenstern Hair Restoration LLC.
• Houston Hair Transplant Center

U.S. PRP And Stem Cell Alopecia Treatment Market Recent Developments

• In March 2024, Stemson Therapeutics signed an exclusive global licensing agreement with the Aderans Company, the parent of Bosley, to develop hair regeneration therapies using Aderans' proprietary cell therapy technology. This partnership allows Stemson to advance Aderans' Phase 2 clinical program for treating Androgenetic Alopecia, integrating it into its own pipeline. Aderans’ technology utilizes patient-derived cells to rejuvenate hair follicles, showing promising results in clinical trials.
• In February 2024, Pelage Pharmaceuticals, a clinical-stage company, secured USD 16.75 million in Series A funding led by GV, with other investors, to develop its novel treatment for androgenetic alopecia and other forms of hair loss. Its lead topical agent, PP405, demonstrated safety, tolerability, and significant activation of hair follicle stem cells in a Phase 1 trial. PP405 works by reactivating dormant stem cells via mitochondrial pyruvate carrier inhibition, enabling hair regrowth.
• In November 2023, The Hair Sciences Center rebranded itself as RESTORE Denver and enhanced its PRP and stem cell alopecia treatment offerings through a strategic partnership with RESTORE Hair. Under the leadership of Dr. James Harris, the center introduced the innovative RESTORE F.U.E. Method, providing patients with advanced hair restoration solutions that minimize recovery time and ensure natural results. This rebranding aims to demonstrate the clinic's commitment to delivering cutting-edge treatments, including PRP therapy, to combat hair loss effectively and improve patient outcomes in the growing market.

Segments Covered in the Report

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2034. For this study, Nova one advisor, Inc. has segmented the U.S. PRP and stem cell alopecia treatment market

By Treatment

• Platelet Rich Plasma Therapy
• Stem Cell Therapy

By Indication

• Androgenic Alopecia
• Alopecia Areata
• Cicatricial Alopecia
• Other Indications

By End-use

• Hospitals
• Dermatology Clinics
• Others

Immediate Delivery Available | Buy This Premium Research https://www.novaoneadvisor.com/report/checkout/9007

Access our Premium Real Time Data Intelligence Tool, Visit: www.precedencestatistics.com

You can place an order or ask any questions, please feel free to sales@novaoneadvisor.com| +1 9197 992 333

About US

Nova One Advisor is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Nova One Advisor has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings.

Connect with Us

Address: Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada

IND Address: 707, Nandan Probiz, Baner,?Pune (MH) – 411045, India

USA:?+1 804 441 9344

APAC:?+61 485 981 310 or +91 87933 22019

Europe:?+44 7383 092 044

Email: sales@novaoneadvisor.com

Web: https://www.novaoneadvisor.com/

You can place an order or ask any questions, please feel free to contact at?sales@novaoneadvisor.com ?| +1 804 441 9344

Nova One Advisor Group Offer Other Reports:

DNA Methylation Market- https://www.biospace.com/press-releases/dna-methylation-market-size-to-hit-usd-6-26-billion-by-2034

Breast Cancer Liquid Biopsy Market -https://www.biospace.com/press-releases/breast-cancer-liquid-biopsy-market-size-to-hit-usd-2-89-billion-by-2034

U.S. Biopharmaceutical Third-party Logistics Market- https://www.biospace.com/press-releases/u-s-biopharmaceutical-third-party-logistics-market-size-to-surpass-usd-99-75-bn-by-203

Pediatric Clinical Trials Market- https://www.biospace.com/press-releases/pediatric-clinical-trials-market-size-to-hit-usd-27-65-billion-by-2033

DNA & Gene Chip Market- https://www.biospace.com/press-releases/dna-gene-chip-market-size-to-hit-around-usd-30-72-billion-by-2033

U.S. Exosomes Market- https://www.biospace.com/press-releases/u-s-exosomes-market-size-to-hit-usd-1-815-46-million-by-2033

Healthcare Patent Filing Outsourcing Market ?https://www.biospace.com/press-releases/healthcare-patent-filing-outsourcing-market-size-to-hit-usd-2-54-bn-by-2034

High Potency API Contract Manufacturing Market https://www.biospace.com/press-releases/high-potency-api-contract-manufacturing-market-size-to-hit-usd-23-00-bn-by-2034

Europe Clinical Trials Market -https://www.biospace.com/press-releases/europe-clinical-trials-market-size-to-hit-usd-43-billion-by-2034

Cell Culture Vessels Market- https://www.biospace.com/press-releases/cell-culture-vessels-market-size-to-surpass-usd-19-65-billion-by-2033

Radiology Information Systems Market https://www.biospace.com/press-releases/radiology-information-systems-market-size-to-hit-usd-3-92-billion-by-2034

In Vitro Diagnostics ( IVD ) Market https://www.biospace.com/press-releases/in-vitro-diagnostics-ivd-market-size-to-surpass-usd-157-56-billion-by-2034

Biological Skin Substitutes Market https://www.biospace.com/press-releases/biological-skin-substitutes-market-size-to-hit-usd-810-50-million-by-2034

Personalized Medicine Biomarkers Market https://www.biospace.com/press-releases/personalized-medicine-biomarkers-market-size-to-hit-usd-79-26-bn-by-2034

Omics-based Clinical Trials Market https://www.biospace.com/press-releases/omics-based-clinical-trials-market-size-to-hit-usd-70-92-billion-by-2034

Radiation Oncology Market https://www.biospace.com/press-releases/radiation-oncology-market-size-share-trends-analysis-report-by-2033

Life Science Tools Market https://www.biospace.com/press-releases/life-science-tools-market-size-share-trends-analysis-report-by-2033

Oncology Clinical Trials Market https://www.biospace.com/press-releases/oncology-clinical-trials-market-size-expected-to-reach-usd-22-11-bn-by-2033

Manufacturing Execution System in Life Sciences Markethttps://www.biospace.com/press-releases/manufacturing-execution-system-in-life-sciences-market-size-to-hit-usd-9-52-bn-by-2034